Canada’s Drug Agency is taking a new step to improve the timeliness of patient access to new drugs. The action supports our ambitious Target Zero campaign — an initiative that aims to achieve zero days between Health Canada’s regulatory approval of a drug and our reimbursement recommendation to…
A new evidence report from Canada’s Drug Agency identifies key factors that influence the ability of older adults in Canada to age in place and the systematic factors to consider when implementing initiatives that can allow people to age at home or in the community.
Aging in place is the ability of…
Current consultation status: Open Consultation period: July 11, 2024, to September 11, 2024
Canada’s Drug Agency is developing pan-Canadian guidance to support decision-making related to newborn screening. This work is being led by our Newborn Screening Advisory Panel and supports the…
Canada’s Drug Agency is advancing our commitment to building meaningful relationships with patient communities by establishing a new Patient Member role on our Board of Directors. Through our open call for nominations, we are seeking a dedicated and experienced individual who will bring new…
Canada’s Drug Agency is announcing recent and upcoming changes to the leadership of our Canadian Drug Expert Committee (CDEC), pan-Canadian Oncology Drug Review Expert Review Committee (pERC), and Patient and Community Advisory Committee (PCAC).
Dr. Peter Jamieson has been appointed incoming Chair…
Canada’s Drug Agency is launching a new 1-year learning period in our Scientific Advice program that will expand the type of guidance we offer to drug manufacturers to include those that are seeking advice after a “do not reimburse” recommendation is issued for their product.
During the learning…
New guidance from an expert panel offers recommendations on minimum retesting intervals for 5 laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.
The guidance may help these organizations implement strategies that support the…
In mid-March, we identified a cybersecurity incident in which an external party gained access to an application in our IT systems. We discovered the incident after an alarm was triggered. We immediately undertook countermeasures to prevent any further unauthorized access or activity and…
Registration is now open for Symposium 2024, a flagship event in the health technology assessment (HTA) community.
Symposium 2024 will be held on September 4 to 6, 2024, and offers both in-person networking and virtual attendance options. The in-person program will take place at the Shaw Centre in…
Health Canada’s Notice of Compliance with conditions (NOC/c) policy has been effective in providing people in Canada with faster access to new oncology drugs based on promising data. A retrospective cohort analysis published in the Canadian Journal of Health Technologies substantiates this by…
As part of our ongoing initiative to improve and modernize our reimbursement review program, Canada’s Drug Agency is introducing the first phase of process improvements related to companion diagnostics.
A companion diagnostic is a class of medical device used alongside a drug that is essential…
Canada’s Drug Agency has published a new report on an economic modelling approach used in evaluations of tumour-agnostic drugs that treat cancer.
The introduction of tumour-agnostic drugs continues to impact cancer treatment and brings additional complexity to the health technology assessment (HTA…